C9108
Anti-Chk2 antibody, Mouse monoclonal
clone DCS-273, purified from hybridoma cell culture
Synonym(s):
Monoclonal Anti-Chk2 antibody produced in mouse
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Conjugate:
unconjugated
Clone:
DCS-273, monoclonal
Application:
ARR, IHC (p), WB
Citations:
11
biological source
mouse
conjugate
unconjugated
antibody form
purified immunoglobulin
antibody product type
primary antibodies
clone
DCS-273, monoclonal
form
buffered aqueous solution
mol wt
antigen 61 kDa
species reactivity
human
concentration
~2 mg/mL
technique(s)
immunohistochemistry (formalin-fixed, paraffin-embedded sections): suitable, microarray: suitable, western blot: 2-4 μg/mL using whole extract of cultured 293T (human embryonal kidney) cells
isotype
IgG1
UniProt accession no.
shipped in
dry ice
storage temp.
−20°C
target post-translational modification
unmodified
Gene Information
human ... CHEK2(11200)
Immunogen
recombinant human Chk2.
Application
Suitable for immunohistochemistry (formalin-fixed, paraffin-embedded sections) and for immunoblotting at a concentration of 2 to 4 μg/mL using whole extract of cultured 293T cells.
Biochem/physiol Actions
The epitope recognized by the antibody resides within the FHA domain of the Chk2 molecule. This epitope is likely to be masked by protein-protein interactions in vivo.
The protein propagates signals from damaged or unreplicated DNA. The protein is expressed throughout the cell cycle. Upon activation it phosphorylates and inhibits CDC25C, which leads to increased inhibitory tyrosine phosphorylation of CDK-cyclin complexes, blocking cell cycle progression. It also regulates apoptosis through the phosphorylation of p53, a tumor suppressor protein. The protein regulates DNA repair through phosphorylation of BRCA2. Mutations in this gene have been linked to Li-Fraumeni syndrome, sarcomas, breast cancer, and brain tumors.
Physical form
Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 1% BSA and 15 mM sodium azide.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Yin Liu et al.
Human mutation, 32(9), 1000-1003 (2011-05-28)
The association between the CHEK2 and breast cancer risk in Chinese women is unknown. Here, we screened the full CHEK2 coding sequence in 118 Chinese familial breast cancer cases who are negative for mutations in BRCA1 and BRCA2, one recurrent
Zuzana Koledova et al.
Stem cells (Dayton, Ohio), 28(3), 450-461 (2010-01-28)
Cyclin-dependent kinase two (Cdk2) is the major regulator of the G1/S transition and the target of an activated G1 checkpoint in somatic cells. In the presence of DNA damage, Cdk2 kinase activity is abrogated by a deficiency of Cdc25A phosphatase
A L Brown et al.
Proceedings of the National Academy of Sciences of the United States of America, 96(7), 3745-3750 (1999-03-31)
Checkpoints maintain the order and fidelity of the eukaryotic cell cycle, and defects in checkpoints contribute to genetic instability and cancer. Much of our current understanding of checkpoints comes from genetic studies conducted in yeast. In the fission yeast Schizosaccharomyces
Vidar Staalesen et al.
Oncogene, 23(52), 8535-8544 (2004-09-14)
The DNA damage checkpoint kinase, CHK2, promotes growth arrest or apoptosis through phosphorylating targets such as Cdc25A, Cdc25C, BRCA1, and p53. Both germline and somatic loss-of-function CHEK2 mutations occur in human tumours, the former linked to the Li-Fraumeni syndrome, and
J Falck et al.
Nature, 410(6830), 842-847 (2001-04-12)
When exposed to ionizing radiation (IR), eukaryotic cells activate checkpoint pathways to delay the progression of the cell cycle. Defects in the IR-induced S-phase checkpoint cause 'radioresistant DNA synthesis', a phenomenon that has been identified in cancer-prone patients suffering from
Related Content
Global Trade Item Number
| SKU | GTIN |
|---|---|
| C9108-.2ML | 04061837867880 |
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service